The short version of Stenabolic fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-14 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
While in power, Renzi implemented several reforms, including a new electoral law (which would later be declared partially unconstitutional by the Constitutional Court), a relaxation of labour and employment laws (known as Jobs Act) with the intention of boosting economic growth, a thorough reform of the public administration, the simplification of the civil trial, the recognition of same-sex unions (not marriages) and the abolition of several minor taxes. As a result of the Libyan civil war, a major problem faced by Renzi was the high level of illegal immigration to Italy. During his tenure, there was an increase in the number of immigrants rescued at sea being brought to southern Italian ports, prompting criticism from the M5S, FI and Northern League (LN), and causing a loss of popularity for Renzi. In the 2018 Italian general election, no political group or party won an outright majority, resulting in a hung parliament. In the election, the right-wing alliance, in which Matteo Salvini's League (LN) emerged as the main political force, won a plurality of seats in the Chamber of Deputies and in the Senate, while the anti-establishment Five Star Movement (M5S) led by Luigi Di Maio became the party with the largest number of votes. The centre-left coalition, led by Matteo Renzi, came third. As a result, protracted negotiations were required before a new government could be formed.
== User-created content == Garry's Mod includes the functionality to modify the game by developing scripts written in the Lua programming language. Notable mods (known as "addons") include Spacebuild, Wiremod, Elevator: Source, DarkRP, Prop Hunt, and Trouble in Terrorist Town. Specialised servers, known as Fretta servers, rotate between custom game modes every fifteen minutes. Garry's Mod version 12 introduced the "Toybox" section, through which the player could browse and install user-created mods. This was replaced by support for the Steam Workshop in version 13.
Also known as the infundibulum or pituitary stalk, the infundibular stalk bridges the hypothalamic and hypophyseal systems. The median eminence is only occasionally included as part of the posterior pituitary. Other sources specifically exclude it from the pituitary. A few sources include the pars intermedia as part of the posterior lobe, but this is a minority view. It is based upon the gross anatomical separation of the posterior and anterior pituitary along the cystic remnants of Rathke's pouch, causing the pars intermedia to remain attached to the neurohypophysis.
Sources: en.wikipedia.org
MHC molecules enable immune system surveillance of the population of protein molecules in a host cell, and greater MHC diversity permits greater diversity of antigen presentation. In 1976, Yamazaki et al demonstrated a sexual selection mate choice by male mice for females of a different MHC. Similar results have been obtained with fish. Some data find lower rates of early pregnancy loss in human couples of dissimilar MHC genes. MHC may be related to mate choice in some human populations, a theory that found support by studies by Ober and colleagues in 1997, as well as by Chaix and colleagues in 2008. However, the latter findings have been controversial. If it exists, the phenomenon might be mediated by olfaction, as MHC phenotype appears strongly involved in the strength and pleasantness of perceived odour of compounds from sweat. Fatty acid esters—such as methyl undecanoate, methyl decanoate, methyl nonanoate, methyl octanoate, and methyl hexanoate—show strong connection to MHC. In 1995, Claus Wedekind found that in a group of female college students who smelled T-shirts worn by male students for two nights (without deodorant, cologne, or scented soaps), the majority of women chose shirts worn by men of dissimilar MHCs, a preference reversed if the women were on oral contraceptives. In 2005 in a group of 58 subjects, women were more indecisive when presented with MHCs like their own, although with oral contraceptives, the women showed no particular preference. No studies show the extent to which odor preference determines mate selection (or vice versa).
Plastic surgery can be performed to augment or reduce the size of breasts, or to reconstruct the breast in cases of deformative disease, such as breast cancer. Breast augmentation and breast lift (mastopexy) procedures are done only for cosmetic reasons, whereas breast reduction is sometimes medically indicated. In cases where a woman's breasts are severely asymmetrical, surgery can be performed to either enlarge the smaller breast, reduce the size of the larger breast, or both. Breast augmentation surgery generally does not interfere with future ability to breastfeed. Breast reduction surgery more frequently leads to decreased sensation in the nipple-areola complex, and to low milk supply in women who choose to breastfeed. Implants can interfere with mammography (breast x-ray images).
While results vary slightly across reputable studies, the consensus is that the mean human penis, when erect, is in the range 5–6 in (13–15 cm) in length. The 2015 review (measured by staff) found average flaccid, stretched, and erect lengths of 9.16 cm (3.61 in), 13.24 cm (5.21 in), and 13.12 cm (5.17 in), respectively, and average flaccid and erect circumferences of 9.31 cm (3.67 in) and 11.66 cm (4.59 in), respectively. Erect length in the studies was measured by pushing the pre-pubic fat pad to the bone, and flaccid or erect girth (circumference) was measured at the base or mid-shaft of the penis.
== Conquest of Sumer == Eannatum, grandson of Ur-Nanshe and son of Akurgal, was a king of Lagash who conquered all of Sumer, including Ur, Nippur, Akshak (controlled by Zuzu), Larsa, and Uruk (controlled by Enshakushanna, who is on the King List). He entered into conflict with Umma, waging a war over the fertile plain of Gu-Edin. He personally commanded an army to subjugate the city-state, and vanquished Ush, the ruler of Umma, finally making a boundary treaty with Enakalle, successor of Ush, as described in the Stele of the Vultures and in the Cone of Entemena:
Sources: en.wikipedia.org
Proteases are involved in digesting long protein chains into shorter fragments by splitting the peptide bonds that link amino acid residues. Some detach the terminal amino acids from the protein chain (exopeptidases, such as aminopeptidases, carboxypeptidase A); others attack internal peptide bonds of a protein (endopeptidases, such as trypsin, chymotrypsin, pepsin, papain, elastase).
== Ductal cell plasticity == There is disagreement about the plasticity potential of ductal cells in the adult pancreas. In the embryonic pancreas, the endocrine and exocrine cells originate in the pancreatic ducts as progenitor cells. In adult ductal cells, there are observations that these cells take on the identity of progenitor cells when stressed. This proposes the idea that there might be a subgroup of ductal cells that have the ability to dedifferentiate and generate endocrine cells when there is an injury to the pancreas. Essentially, ductal cells function in retaining the adult pancreas β cell mass when injured. However, there is a possibility that this capability is limited to a subtype of ductal cells only, meaning this cannot be a main pathway for pancreas regeneration.
== Economy == The Cherokee Nation controls Cherokee Nation Businesses, a holding company which owns companies in gaming, construction, aerospace and defense, manufacturing, technology, real estate, and healthcare industries. The Nation also operates its own housing authority and issues Tribal vehicle and boat tags. The Cherokee Nation's estimated annual economic impact is $1.06 billion on the state's economy, $401 million in salaries, and supports 13,527 Cherokee and non-Cherokee jobs.
== Sources of exposure == Aflatoxin B1 is mostly found in contaminated food and humans are exposed to aflatoxin B1 almost entirely through their diet. Occupational exposure to aflatoxin B1 has also been reported in swine and poultry production. While aflatoxin B1 contamination is common in many staple foods, its production is maximized in foods stored in hot, humid climates. Exposure is therefore most common in Southeast Asia, South America, and Sub-Saharan Africa.
Glycogen storage disease type II (GSD-II), also called Pompe disease, and formerly known as GSD-IIa or Limb–girdle muscular dystrophy 2V, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to a deficiency of the lysosomal acid alpha-glucosidase enzyme (GAA). The inability to break down glycogen within the lysosomes of cells leads to progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver, and the nervous system. GSD-II and Danon disease are the only glycogen storage diseases characterised by a defect in lysosomal metabolism. It was first identified in 1932 by Dutch pathologist Joannes Cassianus Pompe, making it the first glycogen storage disease to be discovered.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.